Sravan Emany
About Sravan K. Emany
Sravan K. Emany (age 47) is an independent director of Assertio Holdings, Inc. (ASRT) since November 2023. He chairs the Audit Committee and serves on the Compensation Committee, with the Board designating him an “audit committee financial expert.” Emany is currently Senior Vice President and Chief Financial Officer of Beam Therapeutics (since December 2024) and previously served as CFO of Ironwood Pharmaceuticals (December 2021–December 2024). He holds a B.A. in international relations from Johns Hopkins and an M.A. in international relations and international economics from Johns Hopkins SAIS.
Past Roles
| Organization | Role | Tenure | Committees/Impact |
|---|---|---|---|
| Beam Therapeutics Inc. | SVP & Chief Financial Officer | Since Dec 2024 | Public-company CFO leadership in biotech |
| Ironwood Pharmaceuticals, Inc. | SVP & Chief Financial Officer | Dec 2021–Dec 2024 | Public-company CFO; healthcare sector experience |
| Integra LifeSciences Holdings Corp. | Corporate VP, Commercial Excellence & Chief Strategy Officer | Mar 2020–Dec 2021 | Corporate strategy; commercial excellence |
| Integra LifeSciences Holdings Corp. | VP, Strategy, Treasury & Investor Relations | Feb 2018–Mar 2020 | Finance, IR, strategy |
| BofA Securities/Bank of America | Investment Banking (M&A), culminating in Managing Director | 2008–2018 | Led numerous healthcare M&A transactions |
| Goldman Sachs; Morgan Stanley | Various financial roles | Not specified | Early-career finance |
External Roles
| Organization | Role | Tenure | Notes |
|---|---|---|---|
| Beam Therapeutics Inc. (Nasdaq) | SVP & Chief Financial Officer | Since Dec 2024 | External operating role; not disclosed as a directorship |
Board Governance
- Committee assignments and roles: Emany chairs Audit; serves on Compensation; Audit members include Sigurd C. Kirk and William T. McKee; Compensation members include Emany, McKee, and Mark L. Reisenauer; Emany, Kirk, and McKee are Audit Committee financial experts.
- Independence: The Board determined Emany is independent under Nasdaq rules and meets heightened independence standards for audit and compensation committees.
- Attendance and engagement: The Board met 9 times in FY2024; Audit met 5; Compensation met 5; Nominating & Corporate Governance met 6. Each director serving during FY2024 (except one who resigned) attended ≥75% of Board and committee meetings and all directors attended the 2024 Annual Meeting.
- Board leadership: Independent Chairman (Heather Mason); CEO is a separate role (Brendan O’Grady).
- Audit oversight: Emany signed the Audit Committee Report recommending inclusion of audited financial statements in the 2024 Form 10-K.
Fixed Compensation
| Component | Amount (USD) | Notes |
|---|---|---|
| Cash fees earned (2024) | $87,561 | Includes base Board retainer and committee chair/member retainers |
| Program context: Board cash retainers | $55,000 (director); +$25,000 (Audit chair); +$10,000 (Compensation member) | Annualized cash retainer structure (paid quarterly, amended Feb 2023/May 2024) |
Performance Compensation
| Equity Type | Grant Value (USD) | Vesting Terms |
|---|---|---|
| Restricted Stock Units (RSUs) (2024) | $54,288 | Vests on earlier of first anniversary of grant or next annual meeting ≥50 weeks after grant; director grants follow this schedule |
| Stock Options (2024) | $72,745 | Same vesting standard as RSUs; options granted at or above fair market value; no repricing without stockholder approval |
- Director equity program design: Non-employee directors received RSUs and options valued at $107,500 each at the 2024 Annual Meeting (share and option counts determined using a $2/share floor and peer-average Black-Scholes factor).
- Change-in-control terms: No single-trigger vesting generally; exceptions include non-employee directors or if a successor refuses to assume/replace awards.
- Clawbacks/dividends: The 2014 Plan prohibits current payment of dividends on unvested awards and allows awards to be subject to clawback under Company policies.
Other Directorships & Interlocks
- No other public-company directorships for Emany are disclosed in the proxy; his external role is an operating position (CFO) at Beam Therapeutics.
Expertise & Qualifications
- Board-designated skills relevant to Assertio: Financial Management; Mergers & Acquisitions; Corporate Strategy; Corporate Management.
- Audit committee financial expert designation.
- Education: B.A. (Johns Hopkins); M.A. in international relations & international economics (Johns Hopkins SAIS).
Equity Ownership
| Metric | Value |
|---|---|
| Common shares beneficially owned | 59,190 |
| Options exercisable within 60 days | 8,770 |
| Ownership as % of shares outstanding | <1% (star notation in proxy) |
| Outstanding options (total) | 107,533 |
| Outstanding RSUs (total) | 172,130 |
| Anti-pledging status | Company policy prohibits pledging; proxy notes no pledges unless otherwise indicated (none indicated for Emany) |
| Stock ownership guideline | Directors must maintain stock equal to 3x annual Board cash retainer; 5 years to comply; directors were in compliance with achieving guidelines within timeframe as of 12/31/2024 |
Governance Assessment
- Independence and oversight strength: Emany is independent and serves as Audit Chair with financial expert designation, enhancing financial reporting oversight and risk management vigilance.
- Engagement: Board and committee meeting cadence in 2024 (9/5/5) and ≥75% attendance support active engagement; all directors attended the 2024 Annual Meeting.
- Alignment and incentives: Director compensation includes cash plus time-based RSUs/options with conservative features (no discounted options, no repricing without stockholder approval, no dividends on unvested awards), and stock ownership guidelines (3x cash retainer) promote alignment.
- Conflicts/related-party exposure: The proxy discloses no related-party transactions involving Emany; the only related-person disclosure pertains to an employee’s relative, with the Audit Committee administering a formal policy.
- Time-commitment consideration: Emany’s concurrent CFO role at Beam (since Dec 2024) is notable for workload; Assertio’s overboarding policy limits are enforced (audit committee members also limited to ≤3 audit committees), and all directors are currently in compliance.
RED FLAGS: None disclosed specific to Emany (no pledging/hedging permitted; no related-party transactions involving him). Continue monitoring for workload/interlocks given external CFO responsibilities and any future related transactions.